LY6E identified as potential immunoprotein against SARS-CoV-2
A study has demonstrated that the LY6E protein inhibits SARS-CoV-2 infection in human cell cultures, so a drug mimicking it could be a therapy for COVID-19.
List view / Grid view
A study has demonstrated that the LY6E protein inhibits SARS-CoV-2 infection in human cell cultures, so a drug mimicking it could be a therapy for COVID-19.
After screening 12,000 existing drugs, scientists have identified 21 which prevent the replication of SARS-CoV-2 in concentrations safe for patients.
Researchers have revealed that the microRNA miR-218-5p promoted hair growth in mice, so is a promising drug target for hair loss.
Dr Santosh Mishra and Srisruti Bontala explain how they discovered a new cutaneous-nerve pathway for allergic itch in atopic dermatitis.
A team has shown that inhibiting the soluble epoxide hydrolase (sEH) enzyme in murine models can prevent the cognitive deterioration associated with Alzheimer's.
According to new research, sulfated polysaccharides extracted from seaweed were more effective at inhibiting SARS-CoV-2 infection in mammalian cells than remdesivir.
Researchers have created a new method of potentially treating herpes virus, by targeting the physical properties of the viral genome.
Researchers have modified the COVID-19 Spike protein for use in vaccines, which produces up to 10 times more protein than that of an earlier synthetic versions.
A new study has shown that while chloroquine protects African green monkey kidney cells from SARS-CoV-2 infection, it does not protect human lung cells.
A novel drug has been created which prevented the blood clotting associated with heart attacks and strokes in pre-clinical studies.
Drug Target Review highlights five of the latest imaging advancements in the field of microscopy.
The vaccine candidate repRNA-CoV2S elicited both antibody and T cell responses after just two injections in mice and macaques.
Researchers reveal IgHV3-53 is the most common immunoglobulin mutation used to target the receptor binding domain on the SARS-CoV-2 spike protein.
Researchers who developed a machine learning algorithm to predict the adverse effects of new drug compounds have released it as an open source tool.
The bioreactor-based system incorporates liver cells to perform the detoxifying functions of the liver and was tested on pigs with acute liver failure.